Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
By P. Ridker, E. Danielson, Francisco A H Fonseca, J. Genest, A. Gotto, J. Kastelein, W. Koenig, Peter Libby, A. Lorenzatti, Jean G Macfadyen and 4 more. The Lancet, 2009
1,030 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/83576e1f6680fd8c41b52f24346e44aebd015165
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- A. Lichtman
- Peter Libby
- G. Hansson
- P. Ridker
- Rhian M. Touyz
- Marja-Riitta Taskinen
- I. Graham
- Gerhard Hindricks
In Epidemiology
- Peter Libby
- P. Ridker
- G. Hansson
- Christian Weber
- A. Lichtman
- Alberico L. Catapano
- I. Graham
- Lina Badimon
In Surgery
- Peter Libby
- G. Hansson
- A. Lichtman
- P. Ridker
- I. Graham
- Marja-Riitta Taskinen
- Alberico L. Catapano
- Ulrich Laufs
Citations in the corpus
- History of Discovery: Inflammation in Atherosclerosis (2012, result): “Prespecified analyses of JUPITER indicated that the clinical benefit derived both from LDL lowering and an antiinflammatory effect reflected by reduction in CRP.(57) These results in an apparently healthy population agreed with previous findings in the clinical trials of patients who survived an acu”
- Inflammation in Atherosclerosis: From Pathophysiology to Practice (2009, background): “(53) This finding has clinical relevance since, in JUPITER, the median on-treatment LDLC was only 55 mg/dL (and 25 percent of the trial had LDLC less than 45 mg/dL), yet optimum benefits not only when LDLC levels reached these very low targets, but when hsCRP levels also fell greatly.”
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “544 The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial(542) demonstrated that in primary prevention for individuals with chronically elevated C-reactive protein (>2 mg/L), statin treatment markedly reduced CV events.(545) It is of no”
- Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans (2013, background): “The use of CRP provided clinical validation of the concept, which emerged from laboratory investigations that statins exhibit direct anti-inflammatory effects, independent of their LDL-lowering properties (Ridker et al., 2009).”
- Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “The clinical benefit is extended to primary prevention in patients with LDL cholesterol levels −1 but elevated hs-CRP, where rosuvastatin significantly reduces major cardiovascular event rates, with reductions in both LDL cholesterol ( −1 ) and hsCRP indicative of successful treatmen”